https://scholars.lib.ntu.edu.tw/handle/123456789/641488
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Lien, Chia En | en_US |
dc.contributor.author | Liu, Ming-Che | en_US |
dc.contributor.author | Wang, Ning-Chi | en_US |
dc.contributor.author | Liu, Luke Tzu-Chi | en_US |
dc.contributor.author | Wu, Chung-Chin | en_US |
dc.contributor.author | Tang, Wei-Hsuan | en_US |
dc.contributor.author | Lian, Wei-Cheng | en_US |
dc.contributor.author | Kuan-Ying A. Huang | en_US |
dc.contributor.author | Chen, Charles | en_US |
dc.date.accessioned | 2024-03-27T07:42:58Z | - |
dc.date.available | 2024-03-27T07:42:58Z | - |
dc.date.issued | 2023-12-01 | - |
dc.identifier.issn | 2076-393X | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/641488 | - |
dc.description.abstract | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines based on variant strains have been in use as booster doses to update immunity against circulating variants. Here we present the results of a phase one prospective, randomized, and open-labeled trial to study the safety and immunogenicity of a booster dose consisting of a subunit vaccine based on the stabilized prefusion SARS-CoV-2 spike protein, MVC-COV1901, or its Beta version, MVC-COV1901-Beta. Participants aged ≥18 and <55 years who received two or three prior doses of MVC-COV1901 vaccines were enrolled and were to receive a booster dose of either 15 mcg of MVC-COV1901, 15 mcg, or 25 mcg of MVC-COV1901-Beta in a 1:1:1 ratio. Adverse reactions after either MVC-COV1901 or MVC-COV1901-Beta booster doses after two or three doses of MVC-COV1901 were comparable and mostly mild and transient. At four weeks after the booster dose, participants with two prior doses of MVC-COV1901 had higher levels of neutralizing antibodies against ancestral SARS-CoV-2, Beta, and Omicron variants than participants with three prior doses of MVC-COV1901, regardless of the type of booster used. MVC-COV1901 and MVC-COV1901-Beta can both be effectively used as booster doses against SARS-CoV-2, including the BA.4/BA.5 Omicron variants. | en_US |
dc.language.iso | en | en_US |
dc.publisher | MDPI | en_US |
dc.relation.ispartof | Vaccines | en_US |
dc.subject | COVID-19; MVC-COV1901; SARS-CoV-2 vaccine; booster vaccination | en_US |
dc.title | Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901-Beta SARS-CoV-2 Vaccine in Adults: A Phase I, Prospective, Randomized, Open-Labeled Study | en_US |
dc.type | journal article | en_US |
dc.identifier.doi | 10.3390/vaccines11121798 | - |
dc.identifier.pmid | 38140202 | - |
dc.identifier.scopus | 2-s2.0-85180650018 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85180650018 | - |
dc.relation.journalvolume | 11 | en_US |
dc.relation.journalissue | 12 | en_US |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Immunology | - |
crisitem.author.orcid | 0000-0001-6891-6945 | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 免疫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。